Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EC Grants Marketing Authorization for Takeda’s ARB Edarbi
December 12, 2011
- Fuso Withdraws NDA for PHN Treatment in Japan, Prepares for Additional Studies
December 12, 2011
- Will Ilaris Remain an “Ultra-orphan” Drug?
December 10, 2011
- DODA Survey Shows MR’s Average Annual Income at ¥6.61 Million, 6th Highest by Occupation
December 9, 2011
- GSK’s Ofatumumab and Pazopanib Granted Orphan Drug Designation
December 9, 2011
- Kyowa Kirin Aims to Make RNAi Drugs Future Pillar: Dr Shitara
December 9, 2011
- Kobayashi, President of Mitsubishi Chemical HD Expects Continuous Growth of Pharmaceutical Business
December 9, 2011
- Takeda Says FDA Committee Indicates Recommendation for Peginesatide
December 9, 2011
- Shionogi Announces Favorable Decision in Fortamet Preliminary Injunction Proceedings
December 9, 2011
- MTPC Sets Up External Committee to Promote Appropriate Use of Telavic
December 8, 2011
- Mebiopharm, Nawaloka HD to Establish Joint Venture in Sri Lanka
December 8, 2011
- Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals
December 7, 2011
- Growth for All Products Is Indispensable: President Alvarez of MSD
December 7, 2011
- FDA Accepts NDA for US BMS/US Pfizer’s Apixaban
December 7, 2011
- US Merck to Establish Asia R&D Headquarters in Beijing
December 7, 2011
- Sandoz Aiming for Top-10 Position in Japan within 3-5 Years
December 7, 2011
- Samsung, Biogen Idec Agree to Set Up Biosimilar Joint Venture Company
December 7, 2011
- Ethical Drug Sales Up 7% in October; 6th Monthly Increase in a Row: Crecon
December 7, 2011
- AnGes MG Reaches Agreement with Japanese, Korean Companies to Develop Therapeutic CIN Vaccine
December 6, 2011
- US Sunovion to Resubmit NDA for Antiepileptic Treatment STEDESA
December 6, 2011
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…